Siemens Healthineers will expand the company’s existing manufacturing operations in Shanghai, China to include a new in vitro diagnostics facility. 

The China manufacturing facility will enable in-country manufacturing capabilities for clinical chemistry and immunoassay reagents.

“This investment demonstrates the company’s continued commitment to address the evolving needs in the Chinese market and in healthcare markets across the globe,” said Franz Walt, President, Laboratory Diagnostics, Siemens Healthineers. 

China is the second largest market for Siemens Healthineers. According to George Chan, President, Greater China, Siemens Healthineers, “The opening of this facility strengthens our ability to support Chinese healthcare reform as we deliver better outcomes at a lower cost to our customers.”

With its opening, Shanghai will become the most integrated base of innovation for the company, covering manufacturing and R&D for imaging diagnostics and lab diagnostics products. Siemens Healthineers expects to employ hundreds of additional employees once the project is complete.